Warfarin, the traditional anticoagulant, has drawbacks such as narrow therapeutic range and frequent monitoring. Direct Oral Anticoagulants (DOAC) address these limitations. DOACs directly inhibit clotting factors, unlike warfarin which indirectly inhibits them. They are preferred due to easier administration, fewer interactions, and superior efficacy. Dabigatran, rivaroxaban, apixaban, and edoxaban are the available DOACs, each with unique attributes and considerations for administration and interactions.